Janux Therapeutics(JANX)
SAN DIEGO, CABiotechnology
Focus: Janux Therapeutics is a publicly traded oncology-focused biotech developing next-generation immunotherapies for cancer, currently in early-stage clinical development with a lean operational footprint.
Profile data last refreshed 21m ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
8+4 this month
Stable — net +4 jobs in 30d
6 added, 2 removed. Backfill posture.
Should You Work at Janux Therapeutics?
AI assessmentBest for early-career oncology and immunology scientists seeking exposure to discovery-stage mechanisms, but career stability depends entirely on clinical trial success and continued public market support.
Why Work Here
- Opportunity to work on novel immunotherapy mechanisms at a company with strong cash position ($431M as of FY2025) supporting 4+ clinical programs
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$8M
Pipeline & Clinical Trials
JANX011
AutoimmuneClinical Trials (1)
NCT07291323Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
Phase 1Help build intelligence for Janux Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.